

# The Bovine Practitioner

Volume 56  
Number 2

2022



The Official Publication  
of the American Association  
of Bovine Practitioners

# Pinkeye Problem? Pinkeye Solution!

## **MAXI/GUARD®**

delivers twice the pinkeye  
protection with  
single dose convenience



### **Broad coverage**

8 different *M. bovis* isolates  
Over 90% efficacy

### **Easy syringeability**

### **Approved for subcutaneous administration**

### **Minimal injection site reactions**

### **Strong safety record**

Extremely low endotoxin levels

### **Single dose protection**



Addison Biological Laboratory, Inc.

800-331-2530

[www.addisonlabs.com](http://www.addisonlabs.com)

[f /AddisonLabs](https://www.facebook.com/AddisonLabs)



# BOVINE PRACTITIONER

Vol 56. NO 2.



*Copy Editor*

**Geni Wren**

1130 East Main St., Ste. 302  
Ashland, OH 44805  
800-269-2227

*Advertising Representative*

**T. O'Brien & Assoc.**

12118 Nieman Road  
Overland Park, KS 66213  
913-579-4084

*Executive Editor*

**K. Fred Gingrich II, DVM**

1130 East Main St., Ste. 302  
Ashland, OH 44805  
419-496-0685

*Publisher*

**Truax Printing, Inc.**

425 East Haskell St.  
Loudonville, OH 44842  
419-994-4166

*Associate Editors*

**Dr. Virginia Fajt**, [dr.fajt@aabp.org](mailto:dr.fajt@aabp.org)

**Dr. Miles Theurer**, [dr.theurer@aabp.org](mailto:dr.theurer@aabp.org)

**Dr. Aurora Villarroel**, [dr.villarroel@aabp.org](mailto:dr.villarroel@aabp.org)

**Dr. Sarah Capik**, [dr.capik@aabp.org](mailto:dr.capik@aabp.org)

---

*The Bovine Practitioner* is the official publication of The American Association of Bovine Practitioners.  
All manuscripts are peer-reviewed. *The Bovine Practitioner* is an open access journal.

©American Association of Bovine Practitioners, 2022 • All Rights Reserved  
*The Bovine Practitioner* • ISSN 0524-1685

## EDITORIAL REVIEW BOARD 2022

AABP would like to thank the below reviewers for volunteering their time and expertise to review articles for *The Bovine Practitioner* for Volume 56.

Reviewers for 2022 include:

Arn Anderson

Jason Banta

Rosslyn Biggs

Dale Blasi

Sébastien Buczinski

Abby Finley

Rebecca Funk

Patrick Gorden

Dale Grotelueschen

Sarah Hamer

Gregg Hanzlicek

David Kelton

Jennifer Koziol

Greta Krafzur

Robert Larson

Katharine Leach

Travis McCarty

Christopher McMullen

Jessica Monday

Bill Pinchak

Ryan Rademacher

Mike Sanderson

Matthew Scott

David Smith

Gerald Stokka

Anthony Tarpoff

Edouard Timsit

Nick Van Engen

Brad White



# Table of Contents

<b>Survey of U.S. cow-calf producer methods and opinions of cattle health and production record-keeping .....</b>	<b>1</b>
<i>W. Isaac Jumper, DVM; Carla L. Huston, DVM, PhD, DACVPM; Robert W. Wills, DVM, PhD, DACVPM; David R. Smith, DVM, PhD, DACVPM</i>	
<b>Survey of U.S. cow-calf producer access to and use of technology for cattle health and production record-keeping purposes.....</b>	<b>16</b>
<i>W. Isaac Jumper, DVM; Carla L. Huston, DVM, PhD, DACVPM; Robert W. Wills, DVM, PhD, DACVPM; David R. Smith, DVM, PhD, DACVPM</i>	
<b>Survey of veterinary involvement in cattle health and production record-keeping on U.S. cow-calf operations.....</b>	<b>29</b>
<i>W. Isaac Jumper, DVM; Carla L. Huston, DVM, PhD, DACVPM, Robert W. Wills, DVM, PhD, DACVPM; David R. Smith, DVM, PhD, DACVPM (Epidemiology)</i>	
<b>Health and performance outcomes from a randomized clinical trial of post-metaphylactic intervals following tildipirosin metaphylaxis for control of naturally occurring bovine respiratory disease in commingled lightweight yearling steers in a commercial feedlot .....</b>	<b>38</b>
<i>Josh I. Szasz, DVM, PhD; Tony C. Bryant, PhD; Lonty K. Bryant, DVM, MS; Marshall N. Streeter,<sup>2</sup> PhD; John P. Hutcheson, PhD; David G. Renter, DVM, PhD</i>	
<b>Failed transfer of passive immunity is a component cause of pre-weaning disease in beef and dairy calves: A systematic review and meta-analysis .....</b>	<b>47</b>
<i>Alexis C. Thompson, DVM; David R. Smith, DVM, PhD, DACVPM</i>	
<b>Maintenance of the last step of the cold chain: on-farm refrigerator storage and performance .....</b>	<b>62</b>
<i>Cynthia A. Fallness, MAg., MFAM, DVM, Dipl. ACVPM; Emmanuel Rollin, DVM, MFAM; Bradley D. Heins, DVM, MFAM; Roy D. Berghaus, DVM, PhD, Dipl. ACVPM</i>	
<b>Seroprevalence and molecular detection of <i>Anaplasma marginale</i> infected beef herds in Georgia, USA .....</b>	<b>70</b>
<i>A. Lee Jones, DVM, MS; Roy D. Berghaus, DVM, PhD, Dip. ACVPM; Allen A. Kalantari, DVM, MS; Brenton Credille, DVM, PhD, DACVIM; Hemant K. Naikare, BVSc &amp; AH, MVSc, PhD, DACVM; Bradley Heins, DVM, MFAM; Jeremiah T. Saliki, DVM, PhD, DACVM; Rebecca P. Wilkes, DVM, PhD, DACVM</i>	





INVESTING IN LONGRANGE® [EPRINOMECTIN]  
DOESN'T JUST TIP THE SCALES IN YOUR FAVOR.  
*IT DARN NEAR BREAKS THEM.*

*PROVEN TO PAY OFF IN  
POUNDS AND DOLLARS.  
CALCULATE THE RETURN  
FOR YOUR HERD.*

Getting more from your dewormer starts with a proven investment. LONGRANGE is the first and only dewormer that provides up to 150 days of parasite control.<sup>1</sup> It's how top producers help their herds pack on the pounds, and in turn, bank more bucks. LONGRANGE is the difference between being average and being at the top of your game. So, next time you're deworming cattle, don't just get the job done. **Get it outdone.**



[thelongrangelook.com/longrange-calculator](https://thelongrangelook.com/longrange-calculator)

*OUTLAST. OUTPERFORM. OUTDO.*

**LONGRANGE IMPORTANT SAFETY INFORMATION:** Do not treat within 48 days of slaughter. Not for use in female dairy cattle 20 months of age or older, including dry dairy cows, or in veal calves. Post-injection site damage (e.g., granulomas, necrosis) can occur. These reactions have disappeared without treatment. Not for use in breeding bulls, or in calves less than 3 months of age. Not for use in cattle managed in feedlots or under intensive rotational grazing.

<sup>1</sup> Dependent upon parasite species, as referenced in FOI summary and LONGRANGE product label.



Extended-Release Injectable Parasiticide  
5% Sterile Solution

For the Treatment and Control of Internal and External Parasites of Cattle on Pasture with Persistent Effectiveness  
Not for use in female dairy cattle 20 months of age or older, including dry dairy cows. Not for use in calves to be processed for veal.

Not for use in breeding bulls, or in calves less than 3 months of age.

Not for use in cattle managed in feedlots or under intensive rotational grazing.

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

**INDICATIONS FOR USE**

LONGRANGE, when administered at the recommended dose volume of 1 mL per 110 lb (50 kg) body weight, is effective in the treatment and control of the following internal and external parasites of cattle:

Gastrointestinal Roundworms	Lungworms
<i>Bunostomum phlebotomum</i> – Adults and L <sub>4</sub>	<i>Dictyoaulus viviparus</i> – Adults
<i>Cooperia oncophora</i> – Adults and L <sub>4</sub>	
<i>Cooperia punctata</i> – Adults and L <sub>4</sub>	
<i>Cooperia surabada</i> – Adults and L <sub>4</sub>	<b>Grubs</b>
<i>Haemonchus placei</i> – Adults	<i>Hypoderma bovis</i>
<i>Oesophagostomum radiatum</i> – Adults	
<i>Ostertagia lyrata</i> – Adults	<b>Mites</b>
<i>Ostertagia ostertagi</i> – Adults, L <sub>4</sub> and inhibited L <sub>4</sub>	<i>Sarcoptes scabiei</i> var. <i>bovis</i>
<i>Trichostrongylus axei</i> – Adults and L <sub>4</sub>	
<i>Trichostrongylus colubriformis</i> – Adults	

Parasites	Durations of Persistent Effectiveness
<b>Gastrointestinal Roundworms</b>	
<i>Bunostomum phlebotomum</i>	150 days
<i>Cooperia oncophora</i>	100 days
<i>Cooperia punctata</i>	100 days
<i>Haemonchus placei</i>	120 days
<i>Oesophagostomum radiatum</i>	120 days
<i>Ostertagia lyrata</i>	120 days
<i>Ostertagia ostertagi</i>	120 days
<i>Trichostrongylus axei</i>	100 days
<b>Lungworms</b>	
<i>Dictyoaulus viviparus</i>	150 days

**DOSAGE AND ADMINISTRATION**

LONGRANGE® (eprinomectin) should be given only by subcutaneous injection in front of the shoulder at the recommended dosage level of 1 mg eprinomectin per kg body weight (1 mL per 110 lb body weight). Each mL of LONGRANGE contains 50 mg of eprinomectin, sufficient to treat 110 lb (50 kg) body weight. Divide doses greater than 10 mL between two injection sites to reduce occasional discomfort or site reaction.

Do not underdose. Ensure each animal receives a complete dose based on a current body weight. Underdosing may result in ineffective treatment, and encourage the development of parasite resistance.

LONGRANGE is to be given subcutaneously only. Animals should be appropriately restrained to achieve the proper route of administration. Inject under the loose skin in front of the shoulder (see illustration) using a 16 or 18 gauge, ½ to ¾ inch needle.

Sanitize the injection site by applying a suitable disinfectant. Clean, properly disinfected needles should be used to reduce the potential for injection site infections.

Body Weight (lb)	Dose Volume (mL)
110	1
220	2
330	3
440	4
550	5
660	6
770	7
880	8
990	9
1100	10



**Withdrawal Periods and Residue Warnings**

Animals intended for human consumption must not be slaughtered within 48 days of the last treatment. This drug product is not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. A withdrawal period has not been established for pre-ruminating calves. Do not use in calves to be processed for veal.

**Animal Safety Warnings and Precautions**

The product is likely to cause tissue damage at the site of injection, including possible granulomas and necrosis. These reactions have disappeared without treatment. Local tissue reaction may result in trim loss of edible tissue at slaughter.

Observe cattle for injection site reactions. If injection site reactions are suspected, consult your veterinarian. This product is not for intravenous or intramuscular use. Protect product from light. LONGRANGE® (eprinomectin) has been developed specifically for use in cattle only. This product should not be used in other animal species.

**When to Treat Cattle with Grubs**

LONGRANGE effectively controls all stages of cattle grubs. However, proper timing of treatment is important. For the most effective results, cattle should be treated as soon as possible after the end of the heel fly (warble fly) season.

**Environmental Hazards**

Not for use in cattle managed in feedlots or under intensive rotational grazing because the environmental impact has not been evaluated for these scenarios.

**Other Warnings:** Parasite resistance may develop to any dewormer, and has been reported for most classes of dewormers.

Treatment with a dewormer used in conjunction with parasite management practices appropriate to the geographic area and the animal(s) to be treated may slow the development of parasite resistance.

Fecal examinations or other diagnostic tests and parasite management history should be used to determine if the product is appropriate for the herd/flock, prior to the use of any dewormer. Following the use of any dewormer, effectiveness of treatment should be monitored (for example, with the use of a fecal egg count reduction test or another appropriate method).

A decrease in a drug's effectiveness over time as calculated by fecal egg count reduction tests may indicate the development of resistance to the dewormer administered. Your parasite management plan should be adjusted accordingly based on regular monitoring.

Macrocyclic lactones provide prolonged drug exposure that may increase selection pressure for resistant parasites. This effect may be more pronounced in extended-release formulations.

**TARGET ANIMAL SAFETY**

Clinical studies have demonstrated the wide margin of safety of LONGRANGE® (eprinomectin). Overdosing at 3 to 5 times the recommended dose resulted in a statistically significant reduction in average weight gain when compared to the group tested at label dose. Treatment-related lesions observed in most cattle administered the product included swelling, hyperemia, or necrosis in the subcutaneous tissue of the skin. The administration of LONGRANGE at 3 times the recommended therapeutic dose had no adverse reproductive effects on beef cows at all stages of breeding or pregnancy or on their calves.

Not for use in bulls, as reproductive safety testing has not been conducted in males intended for breeding or actively breeding. Not for use in calves less than 3 months of age because safety testing has not been conducted in calves less than 3 months of age.

**STORAGE**

Store at 77° F (25° C) with excursions between 59° and 86° F (15° and 30° C). Protect from light.

Approved by FDA under NADA # 141-327

Made in Canada.

Manufactured for Boehringer Ingelheim Animal Health USA Inc., Duluth, GA 30096

®The Cattle Head Logo and ®LONGRANGE are registered trademarks of

Boehringer Ingelheim Animal Health USA Inc.

© 2019 Boehringer Ingelheim Animal Health USA Inc. All rights reserved.

1050-2889-08, Rev. 01/2019, 8L0N016E US-B0V-0597-2021A





# ONE DOSE. 30 MINUTES.

Knock out BRD in one dose with Zactran® (gamithromycin). ZACTRAN reaches the lungs in 30 minutes to start fighting BRD at the site of infection,<sup>1</sup> compared to 3 hours for tulathromycin.<sup>2</sup> It works fast, hitting peak concentration in just 12 hours,\*\* with cattle health typically improving in 24 hours.\*\*\*<sup>3</sup> But the fight doesn't stop there: One dose of ZACTRAN delivers 10 days of treatment.<sup>4</sup> Make the quick treatment choice, and get your cattle healthy fast.

Treat BRD quickly at [ZACTRAN.com](http://ZACTRAN.com)

**IMPORTANT SAFETY INFORMATION:** For use in cattle only. Do not treat cattle within 35 days of slaughter. Do not use in female dairy cattle 20 months of age or older, or in calves to be processed for veal. Subcutaneous injection may cause a transient local tissue reaction in some cattle that may result in trim loss of edible tissues at slaughter.

\*Clinical relevance has not been determined. \*\*Time to T<sub>max</sub> in the lung. \*\*\*A small percentage of cattle may have already suffered lung damage, and may be too far gone or will require a little longer to turn around. <sup>1</sup>Giguere S, Huang R, Malinski TJ, et al. Disposition of gamithromycin in plasma, pulmonary epithelial lining fluid, bronchoalveolar cells and lung tissue in cattle. *Am J Vet Res* 2011;72(3):326-330. <sup>2</sup>Cox SR, McLaughlin C, Fielder AE, Yancey MF. Rapid and prolonged distribution of tulathromycin into lung homogenate and pulmonary epithelial lining fluid of holstein calves following a single subcutaneous administration of 2.5mg/kg body weight. *J Appl Res Vet Med* 2010; 8(3):129-137. <sup>3</sup>Sifferman RL, Wolff WA, Holste JE, et al. Field efficacy evaluation of gamithromycin for treatment of bovine respiratory disease in cattle at feedlots. *Intern J Appl Res Vet Med* 2011;9(2):166-175. <sup>4</sup>ZACTRAN product label.

ZACTRAN® is a registered trademark of Boehringer Ingelheim Animal Health France, used under license. ©2023 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All Rights Reserved. US-BOV-0576-2022A

Cattle First.



**30**  
MINUTES  
TO THE SITE  
OF INFECTION\*\*

**12**  
HOURS  
TO PEAK  
CONCENTRATION\*\*

**ZACTRAN®**  
(gamithromycin)

150 mg/mL ANTIMICROBIAL

For subcutaneous injection in beef and non-lactating dairy cattle only. Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal.

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

See page 10 for a complete list of contraindications, warnings, and precautions. For more information, visit [ZACTRAN.com](http://ZACTRAN.com). **INDICATIONS:** ZACTRAN is indicated for the treatment of BRD in beef and non-lactating dairy cattle. **DOSE:** 12 mL (0.18 g) subcutaneously. **WARNINGS:** Do not use in female dairy cattle 20 months of age or older, or in calves to be processed for veal. **RESIDUES:** Residues are not expected to be present in edible tissues. **STORAGE:** Store at room temperature.

# ZACTRAN<sup>®</sup>

(gamithromycin)

## 150 mg/mL ANTIMICROBIAL

NADA 141-328, Approved by FDA

For subcutaneous injection in beef and non-lactating dairy cattle only. Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal.

**Caution:** Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

**READ ENTIRE BROCHURE CAREFULLY BEFORE USING THIS PRODUCT.**

### INDICATIONS

ZACTRAN is indicated for the treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica*, *Pasteurella multocida*, *Histophilus somni* and *Mycoplasma bovis* in beef and non-lactating dairy cattle. ZACTRAN is also indicated for the control of respiratory disease in beef and non-lactating dairy cattle at high risk of developing BRD associated with *Mannheimia haemolytica* and *Pasteurella multocida*.

### CONTRAINDICATIONS

As with all drugs, the use of ZACTRAN is contraindicated in animals previously found to be hypersensitive to this drug.

**WARNING: FOR USE IN CATTLE ONLY. NOT FOR USE IN HUMANS. KEEP THIS AND ALL DRUGS OUT OF REACH OF CHILDREN. NOT FOR USE IN CHICKENS OR TURKEYS.**

### DOSAGE AND ADMINISTRATION

Administer ZACTRAN one time as a subcutaneous injection in the neck at 6 mg/kg (2 mL/110 lb) body weight (BW). If the total dose exceeds 10 mL, divide the dose so that no more than 10 mL is administered at each injection site.

Body Weight (lb)	Dose Volume (mL)
110	2
220	4
330	6
440	8
550	10
660	12
770	14
880	16
990	18
1100	20

Animals should be appropriately restrained to achieve the proper route of administration. Use sterile equipment. Inject under the skin in front of the shoulder (see illustration).



The Safety Data Sheet (SDS) contains more detailed occupational safety information. To report suspected adverse drug events, for technical assistance, or to obtain a copy of the SDS, contact Boehringer Ingelheim Animal Health USA Inc. at 1-888-637-4251. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS, or online at [www.fda.gov/reportanimalae](http://www.fda.gov/reportanimalae).

**RESIDUE WARNINGS:** Do not treat cattle within 35 days of slaughter. Because a discard time in milk has not been established, do not use in female dairy cattle 20 months of age or older. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.

### PRECAUTIONS

The effects of ZACTRAN on bovine reproductive performance, pregnancy, and lactation have not been determined. Subcutaneous injection of ZACTRAN may cause a transient local tissue reaction in some cattle that may result in trim loss of edible tissues at slaughter.

### ADVERSE REACTIONS

Transient animal discomfort and mild to moderate injection site swelling may be seen in cattle treated with ZACTRAN.

### EFFECTIVENESS

For information on effectiveness, the product label in full can be found at [https://www.zactran.com/sites/default/files/pdfs/Zactan\\_Label.pdf](https://www.zactran.com/sites/default/files/pdfs/Zactan_Label.pdf).

**Marketed by Boehringer Ingelheim Animal Health USA Inc.**

Duluth, GA 30096

Made in Austria

®ZACTRAN is a registered trademark of the Boehringer Ingelheim Group.

©2019 Boehringer Ingelheim Animal Health USA Inc. All rights reserved.

M088812/03 US Code 6411 Rev. 01/2019